Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 994,525 | 521,870 | 598,912 | 713,971 | 374,685 |
| Receivables | 1,643 | 1,970 | 1,936 | 2,084 | 2,224 |
| TOTAL | $1,042,939 | $573,546 | $651,763 | $767,760 | $412,541 |
| Non-Current Assets | |||||
| PPE Net | 531 | 632 | 737 | 844 | 752 |
| Other Non-Current Assets | 8,922 | 8,781 | 8,940 | 7,618 | 7,639 |
| TOTAL | $9,453 | $9,413 | $9,677 | $8,462 | $8,391 |
| Total Assets | $1,052,392 | $582,959 | $661,440 | $776,222 | $420,932 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 8,616 | 6,916 | 7,843 | 17,656 | 19,816 |
| Accrued Expenses | 57,641 | 56,338 | 45,057 | 51,119 | 48,476 |
| TOTAL | $66,257 | $63,254 | $52,900 | $68,775 | $68,315 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $66,257 | $63,254 | $52,900 | $68,775 | $68,315 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 203,532 | 175,277 | 174,317 | 170,923 | 169,861 |
| Common Shares | 20 | 17 | 16 | 16 | 14 |
| Retained earnings | -1,597,273 | -1,486,638 | -1,360,136 | -1,239,523 | -1,133,074 |
| Other shareholders' equity | 1,197 | 1,450 | 1,737 | 1,459 | 2,479 |
| TOTAL | $986,135 | $519,705 | $608,540 | $707,447 | $352,617 |
| Total Liabilities And Equity | $1,052,392 | $582,959 | $661,440 | $776,222 | $420,932 |